Full Title
A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial (MM1OA-EA02) (CIRB)Purpose
Researchers want to see if adding gilteritinib to two other drugs works better than the other drugs alone for leukemia. The people in this study include older and unfit adults with acute myeloid leukemia (AML). In addition, their AML has a mutation (change) in a gene called FLT3.
Azacitidine turns on genes that help control cell growth. It is given intravenously (by vein) or by injection.
Venetoclax blocks Bcl-2, a protein needed for cancer cell survival. Gilteritinib blocks a growth signal that helps certain cancer cells multiply. Venetoclax and gilteritinib are taken orally (by mouth).
If you join this study, you will be randomly assigned to get azacitidine and venetoclax alone (standard treatment), or to get the standard treatment with gilteritinib.
Who Can Join
To join this study, there are a few conditions. You must:
- Be age 60 or older and have FLT3-mutated AML. If you are under 60, your doctor must have indicated that you are better suited for less intensive leukemia treatment.
- Have not had prior therapy for AML, with the exception of hydroxyurea and all-trans retinoic acid (ATRA), or leukapheresis.
Contact
For more information and to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.